Citadel Advisors’s Mural Oncology MURA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-12,400
Closed -$25.7K 13586
2025
Q3
$25.7K Sell
12,400
-4,900
-28% -$10.5K ﹤0.01% 12438
2025
Q2
$42.7K Sell
17,300
-300
-2% -$707 ﹤0.01% 11846
2025
Q1
$22.2K Buy
+17,600
New +$64.2K ﹤0.01% 13069
2024
Q4
Sell
-4,000
Closed -$12.5K 15077
2024
Q3
$12.5K Buy
4,000
+2,000
+100% +$6.51K ﹤0.01% 13104
2024
Q2
$6.28K Buy
+2,000
New +$7.37K ﹤0.01% 13343

Citadel Advisors's MURA Position: Q4 2025 in Review

Citadel Advisors sold out of Mural Oncology (MURA) in Q4 2025, closing a stake of 258,250 shares — an estimated $535K sold.

Citadel Advisors first reported a position in MURA in Q4 2023 and held it in 7 quarters. The position peaked at $1.47M in Q4 2023. 0 funds tracked by Wall St. Rank hold MURA as of Q4 2025.

  • Citadel Advisors reported no remaining Mural Oncology position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 258,250 Mural Oncology shares in Q4 2025, an estimated $535K.
  • Citadel Advisors first reported a position in Mural Oncology in Q4 2023 and held it in 7 quarters.
  • Citadel Advisors's Mural Oncology position peaked at $1.47M in Q4 2023.
  • 0 funds tracked by Wall St. Rank held Mural Oncology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.